Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: A systematic review and meta-analysis

Use of incretin agents and risk of pancreatic cancer: a population-based cohort study

(2016) L. M. Knapen et al.   DIABETES OBESITY & METABOLISM

Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors

(2016) Phyo T. Htoo et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study

(2016) Laurent Azoulay et al.   BMJ-British Medical Journal

Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study

(2016) Laurent Azoulay et al.   BMJ-British Medical Journal

Incretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials

(2016) Han Chen et al.   Diabetes Therapy

Incretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials

(2016) Han Chen et al.   Diabetes Therapy

Influence of metformin intake on the risk of bladder cancer in type 2 diabetes patients

(2015) Maria E. Goossens et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION)

(2015) G. Schernthaner et al.   DIABETES OBESITY & METABOLISM

Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial

(2015) L. A. Leiter et al.   DIABETES OBESITY & METABOLISM

Sitagliptin and pancreatic cancer risk in patients with type 2 diabetes

(2015) Chin-Hsiao Tseng   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

An Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers

(2015) Chin-Hsiao Tseng et al.   JOURNAL OF ENVIRONMENTAL SCIENCE AND HEALTH PART C-ENVIRONMENTAL CARCINOGENESIS & ECOTOXICOLOGY REVIEWS

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

(2015) Jennifer B. Green et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of linagliptin monotherapy in Asian patients with inadequately controlled type 2 diabetes mellitus: A multinational, 24-week, randomized, clinical trial

(2015) Yuhong Chen et al.   Journal of Diabetes Investigation

Incretin-mimetic therapies and pancreatic disease: a review of observational data

(2014) Elizabeth A. Suarez et al.   CURRENT MEDICAL RESEARCH AND OPINION

Efficacy and Safety of the Once-Weekly GLP-1 Receptor Agonist Albiglutide Versus Sitagliptin in Patients With Type 2 Diabetes and Renal Impairment: A Randomized Phase III Study

(2014) Lawrence A. Leiter et al.   DIABETES CARE

HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin

(2014) Bo Ahrén et al.   DIABETES CARE

Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)

(2014) Michael Nauck et al.   DIABETES CARE

Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study

(2014) M. Gokhale et al.   DIABETES OBESITY & METABOLISM

Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged ≥ 65 years

(2014) G. Schernthaner et al.   DIABETES OBESITY & METABOLISM

Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with Type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study

(2014) M. Bajaj et al.   DIABETIC MEDICINE

Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?

(2014) Jocelyn de Heer et al.   Expert Opinion On Drug Safety

Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment

(2014) Amy G. Egan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: Data from the Italian AIFA Anti-diabetics Monitoring Registry

(2014) S. Montilla et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

A Critical Analysis of the Clinical Use of Incretin-Based Therapies: Are the GLP-1 therapies safe?

(2013) P. C. Butler et al.   DIABETES CARE

A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs

(2013) D. Funch et al.   DIABETES OBESITY & METABOLISM

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

(2013) William B. White et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency

(2012) J. C. Arjona Ferreira et al.   DIABETES CARE

Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension

(2012) A. H. Barnett et al.   DIABETES OBESITY & METABOLISM

A meta-analysis of serious adverse events reported with exenatide and liraglutide: Acute pancreatitis and cancer

(2012) Carlos Alves et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence

(2012) J. A. Johnson et al.   DIABETOLOGIA

Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial

(2012) Pablo Aschner et al.   LANCET

Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52 weeks

(2012) Takashi Kadowaki et al.   Journal of Diabetes Investigation

Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study

(2012) Yutaka Seino et al.   Journal of Diabetes Investigation

Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias

(2011) J. A. Johnson et al.   DIABETOLOGIA

Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies

(2011) Michael Elashoff et al.   GASTROENTEROLOGY

One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial

(2011) R. Pratley et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients*

(2011) Mathijs C. BUNCK et al.   Journal of Diabetes

Diabetes, Insulin Use, and Cancer Risk: Are Observational Studies Part of the Solution-or Part of the Problem?

(2010) J. A. Johnson et al.   DIABETES

Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement

(2010) David Moher et al.   International Journal of Surgery

Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus

(2009) Masatoshi Kikuchi et al.   DIABETES RESEARCH AND CLINICAL PRACTICE